Titre : | Efficacity of tDCS in catatonic patients with Phelan McDermid syndrome, a case series |
Auteurs : | Mylène Moyal, Aut. ; Marion Plaze, Aut. ; Ambre Baruchet, Aut. ; David ATTALI, Aut. ; Cora Cravero, Aut. ; Marie Raffin, Aut. ; Angèle Consoli, Aut. ; David Cohen, Aut. ; Alexandre HAROCHE, Aut. ; Boris Chaumette, Aut. |
Année de publication : | 2022 |
Pagination : | 1432-1434 |
Note générale : | BRAIN STIMULATION, 15(6) |
Langues: | Anglais |
Mots-clés : |
Noms propres STIMULATION TRANSCRANIENNE PAR COURANT CONTINUSANTEPSY CAS CLINIQUE ; CATATONIE ; NEUROSTIMULATION ; TROUBLE NEURODEVELOPPEMENTAL |
Résumé : | To the Editor: Phelan-McDermid syndrome (PMS) is a rare disorder characterized by deletion or mutation of the SHANK3 gene located in the chromosomal region 22q13.33. It is associated with catatonia in 53% of cases [1]. In neurodevelopmental disorders like PMS, under-diagnosis and lack of prompt management lead to chronicity of the catatonic episode [2], a factor associated with poor therapeutic response to the two standard treatments: lorazepam and electroconvulsive therapy (ECT). Despite Expert Therapeutic Recommendations (https://pmsf.org/), effective and well-tolerated cares for chronic catatonia in PMS are still lacking. Furthermore, in PMS, benzodiazepines such as lorazepam, while reducing catatonic symptoms, may increase impulsivity, psychomotor arousal, confusion and insomnia limiting the use of this treatment [3]. ECT is also sometimes not available or contraindicated. Transcranial direct current stimulation (tDCS), an easy-to-apply noninvasive brain stimulation technique, has been shown to be effective and safe in neurodevelopmental disorders [4] and in twelve cases of catatonic patients [5]. In this letter, we present the efficacy and safety of tDCS in four cases of catatonia occurring on PMS. [premières lignes] |
En ligne : | https://go.openathens.net/redirector/ghu-paris.fr?url=https://www.sciencedirect.com/science/article/pii/S1935861X22002285 |
Service de l'auteur du GHU : |
Service Hospitalo-Universitaire (SHU) /Centre référent maladies rares à expression psychiatrique (CRMRpsy) |